Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eprosartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.91 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.91 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprosartan SCHEMBL1504815 | 1.00 | AGTR1 (0.91) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1504814 | 1.00 | AGTR1 (0.91) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL4382107 | 1.00 | AGTR1 (0.91) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL41397 | 0.99 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL41396 | 0.99 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL3972893 | 0.99 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL5785067 | 0.99 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL74813 | 0.96 | AGTR1 (0.92) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL7405236 | 0.96 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1119965 | 0.96 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991647-B1 | EPROSARTAN MONOHYDRATE | SMITHKLINE BEECHAM CORP (US) | 2002-09-04 | — | — | EP | claimed |
| US-6262102-B1 | USING THE COMPOUND TO BLOCK ANGIOTENSIN II RECEPTORS AND TO TREAT HYPERTENSION, CONGESTIVE HEART FAILURE AND RENAL FAILURE. | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | claimed |
| WO-2009084028-A2 | IMPROVED PROCESS FOR MANUFACTURING ANHYDROUS (E)-3-[2-BUTYL-1- {(4-CARBOXYPHENYL) METHYL}-1H-IMIDAZOLE-5-YL]-(THIOPHEN-2- YLMETHYL)PROP-2-ENOIC ACID METHANE SULFONATE | NEULAND LABORATORIES LTD (IN) | 2009-07-09 | — | — | WO | disclosed |
| US-20040138278-A1 | Use of AT1 receptor antagonists for prevention of subsequent strokes | SOLVAY PHARMACEUTICALS GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| EP-0991647-B1 | EPROSARTAN MONOHYDRATE | SMITHKLINE BEECHAM CORP (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-0991647-B1 | EPROSARTAN MONOHYDRATE | SMITHKLINE BEECHAM CORP (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-0991647-A4 | EPROSARTAN MONOHYDRATE | SMITHKLINE BEECHAM CORP (US) | 2001-08-16 | — | — | EP | disclosed |
| EP-0991647-A4 | EPROSARTAN MONOHYDRATE | SMITHKLINE BEECHAM CORP (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6262102-B1 | USING THE COMPOUND TO BLOCK ANGIOTENSIN II RECEPTORS AND TO TREAT HYPERTENSION, CONGESTIVE HEART FAILURE AND RENAL FAILURE. | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-0991647-A1 | EPROSARTAN MONOHYDRATE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0991647-A1 | EPROSARTAN MONOHYDRATE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999000383-A1 | EPROSARTAN MONOHYDRATE | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1999000383-A1 | EPROSARTAN MONOHYDRATE | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-07 | — | — | WO | disclosed |